Eyes have it: Avalanche Bio inks $640 million-plus Regeneron gene therapy deal

The San Francisco company, which last month raised $55 million , will work with Tarrytown, N.Y.-based Regeneron to discover, develop and commercialize gene therapies for eye diseases, earning an undisclosed upfront cash payment and development and regulatory milestones of up to $640 million.

http://ift.tt/1kIo9SV